Dowling & Yahnke LLC Ionis Pharmaceuticals Inc Transaction History

Dowling & Yahnke LLC

$215 Million
Q3 2022

A detailed history of Dowling & Yahnke LLC transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Dowling & Yahnke LLC holds 302,571 shares of IONS stock, worth $10.8 Million. This represents 6.23% of its overall portfolio holdings.

Number of Shares

302,571

Previous 302,571 -0.0%

Holding current value

$10.8 Million

Previous $11.2 Million 19.48%

% of portfolio

6.23%

Previous 0.53%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 04, 2022	BUY	$29.88 - $37.04 $4,482 - $5,556	150 Added 0.05%	302,571 $11.2 Million
Q4 2021 Feb 10, 2022	SELL	$25.61 - $35.1 $2,561 - $3,510	-100 Reduced 0.03%	302,421 $9.2 Million
Q3 2021 Nov 12, 2021	SELL	$33.54 - $40.55 $21,096 - $25,505	-629 Reduced 0.21%	302,521 $10.1 Million
Q2 2021 Jul 21, 2021	SELL	$34.54 - $47.25 $2,417 - $3,307	-70 Reduced 0.02%	303,150 $12.1 Million
Q1 2021 Apr 29, 2021	SELL	$42.51 - $63.78 $7.32 Million - $11 Million	-172,241 Reduced 36.23%	303,220 $13.6 Million
Q4 2020 Jan 28, 2021	SELL	$45.3 - $60.27 $4.53 Million - $6.03 Million	-100,017 Reduced 17.38%	475,461 $26.9 Million
Q3 2020 Oct 19, 2020	SELL	$47.45 - $62.95 $4.75 Million - $6.3 Million	-100,000 Reduced 14.8%	575,478 $27.3 Million
Q3 2018 Oct 30, 2018	BUY	$42.88 - $53.7 $728 - $912	17 Added 0.0%	675,478 $34.8 Million
Q2 2018 Jul 30, 2018	SELL	$40.53 - $50.7 $20,265 - $25,350	-500 Reduced 0.07%	675,461 $28.1 Million
Q1 2018 May 01, 2018	BUY	$44.08 - $55.05 $3,085 - $3,853	70 Added 0.01%	675,961 $29.8 Million
Q3 2017 Nov 08, 2017	BUY	$45.56 - $59.57 $30.8 Million - $40.3 Million	675,891	675,891 $34.3 Million

Others Institutions Holding IONS

# of Institutions

402

Shares Held

136M

Call Options Held

862K

Put Options Held

582K

View Full List

About IONIS PHARMACEUTICALS INC

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $5.06B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

More about IONS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dowling & Yahnke LLC, based on Form 13F filings with the SEC.

News

Stay updated on Dowling & Yahnke LLC with notifications on news.

Account

Dowling & Yahnke LLC Ionis Pharmaceuticals Inc Transaction History